Blood pressure lowering efficacy of aliskiren
High blood pressure is a chronic condition associated with an increased risk of cardiovascular disease and death. Over the last two decades, the Cochrane Hypertension Group has produced numerous reviews of ways to treat it, including one of the effects of a class of drugs called renin inhibitors. The review was updated in April 2017 and we asked the lead author, Vijaya Musini from the University of British Columbia in Vancouver Canada, to tell us about the latest findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - September 14, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.
Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the September 18, 2013 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - September 17, 2013 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
#138: FDA: No aliskiren with ACE inhibitors, ARBs in some patients; cardiologists: high income, many frustrations; TIPS 2 on full-dose polypill; ESC paper on new anticoagulants; Bahrain AED survey points to CPR barriers
FDA: No aliskiren with ACE inhibitors, ARBs in some patients; cardiologists: high income, many frustrations; TIPS 2 on full-dose polypill; ESC paper on new anticoagulants; Bahrain AED survey points to CPR barriers (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - April 27, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#129: ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies
ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - February 24, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
